Prodotti competitors
Minutes from the EMA’s Committee for Medicinal Products for Human Use (CHMP) released on the 19th of May 2023: Lagevrio – molnupiravir
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Re-examination of initial application procedures
Lagevrio – molnupiravir
Merck Sharp & Dohme B.V
- Treatment of coronavirus disease 2019 (COVID-19)
- The CHMP appointed a re-examination rapporteur and a re-examination Co-Rapporteur.
Grazie per il tuo feedback!